Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short

1. Eli Lilly's Q4 profit exceeded estimates but revenue slightly missed. 2. Adjusted EPS of $5.32 beat predictions of $5.11. 3. Sales for Mounjaro and Zepbound fell short of expectations. 4. 2025 revenue outlook is strong, projected between $58.0 to $61.0 billion. 5. Shares rose over 2% post-report, outperforming competitor Novo Nordisk.